| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Harald Hampel | Q38328382 |
| P2093 | author name string | Karl Broich | |
| Johannes Pantel | |||
| Yvonne Hoessler | |||
| P2860 | cites work | Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease | Q79652573 |
| Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia | Q79854193 | ||
| A default mode of brain function | Q24544311 | ||
| A perfect correlate does not a surrogate make | Q24803339 | ||
| The human brain is intrinsically organized into dynamic, anticorrelated functional networks | Q27860802 | ||
| Voxel-based morphometry–the methods | Q28138780 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI | Q29619152 | ||
| Investigating the neural basis for functional and effective connectivity. Application to fMRI. | Q30498611 | ||
| Magnetic resonance spectroscopy in AD. | Q30640894 | ||
| A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. | Q30708048 | ||
| Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease | Q31032564 | ||
| Principles of diffusion tensor imaging and its applications to basic neuroscience research | Q31058696 | ||
| Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. | Q51914558 | ||
| Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. | Q51924516 | ||
| Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. | Q51924803 | ||
| Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. | Q51944474 | ||
| Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. | Q51978821 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. | Q52001947 | ||
| Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. | Q52020527 | ||
| Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. | Q52029709 | ||
| Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. | Q52921824 | ||
| Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. | Q53255745 | ||
| Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. | Q53264910 | ||
| Plasma Abeta in Alzheimer's disease--up or down? | Q53279457 | ||
| Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. | Q53279641 | ||
| Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. | Q53285087 | ||
| Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. | Q53289074 | ||
| Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. | Q53363278 | ||
| Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. | Q53375835 | ||
| Selective Reductions in Plasma A 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report | Q57317953 | ||
| Hippocampus and entorhinal cortex in mild cognitive impairment and early AD | Q59542878 | ||
| Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Neuromedizin | Q60607110 | ||
| Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains | Q64361128 | ||
| Estimation of metabolite concentrations from localized in vivo proton NMR spectra | Q72319396 | ||
| Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group | Q74477356 | ||
| Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk | Q79279445 | ||
| White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques | Q31110382 | ||
| Metabolite-specific NMR spectroscopy in vivo. | Q32067982 | ||
| An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid | Q33260793 | ||
| Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease | Q33594005 | ||
| Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study | Q34287865 | ||
| Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. | Q34408719 | ||
| Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease | Q34509732 | ||
| The FDA critical path initiative and its influence on new drug development. | Q34734622 | ||
| Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease | Q35114490 | ||
| CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease? | Q35136034 | ||
| A voxel based morphometry study on mild cognitive impairment | Q35483542 | ||
| Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. | Q35486482 | ||
| CSF markers for incipient Alzheimer's disease | Q35541472 | ||
| Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease | Q35572392 | ||
| Imaging Alzheimer's disease: clinical applications | Q35692950 | ||
| Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD | Q35749793 | ||
| Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia | Q35749798 | ||
| Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease | Q35928563 | ||
| Biomarkers and surrogate markers: an FDA perspective | Q36045270 | ||
| Biomarkers of Alzheimer disease in plasma | Q36045288 | ||
| Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment | Q36447010 | ||
| Imaging of muscarinic receptors in the central nervous system | Q36638800 | ||
| Biochemistry and molecular biology of tauopathies | Q36642466 | ||
| Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease | Q36993185 | ||
| Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment | Q37313709 | ||
| Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease | Q37402317 | ||
| Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study | Q37407266 | ||
| Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease | Q37486254 | ||
| Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. | Q38430049 | ||
| Differential aging of the medial temporal lobe: a study of a five-year change | Q39675967 | ||
| Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease | Q40190874 | ||
| Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 | ||
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
| A new method for the in vivo volumetric measurement of the human hippocampus with high neuroanatomical accuracy | Q40730214 | ||
| Surrogate end points in clinical trials: are we being misled? | Q41117631 | ||
| Amyloid beta-peptide is produced by cultured cells during normal metabolism | Q41602809 | ||
| Proton NMR chemical shifts and coupling constants for brain metabolites | Q41742652 | ||
| Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region | Q42452337 | ||
| In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease | Q42456070 | ||
| A new rating scale for age-related white matter changes applicable to MRI and CT. | Q42505285 | ||
| In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease | Q43684436 | ||
| (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. | Q43701809 | ||
| Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease | Q43767488 | ||
| Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease | Q43999943 | ||
| Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. | Q44091581 | ||
| CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects | Q44115118 | ||
| Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing | Q45209773 | ||
| Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. | Q46019129 | ||
| Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease | Q46481511 | ||
| Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index | Q46502975 | ||
| Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. | Q46856839 | ||
| No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease | Q48113706 | ||
| Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study | Q48137573 | ||
| Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment | Q48147007 | ||
| Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. | Q48208608 | ||
| Plasma Abeta levels do not reflect brain Abeta levels | Q48214768 | ||
| A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression | Q48228877 | ||
| High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease | Q48233908 | ||
| Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study | Q48339997 | ||
| Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls | Q48373578 | ||
| CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study | Q48381623 | ||
| Parahippocampal volume deficits in subjects with aging-associated cognitive decline. | Q48397087 | ||
| CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease | Q48408159 | ||
| A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease | Q48420535 | ||
| Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment | Q48461562 | ||
| CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. | Q48494001 | ||
| Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial | Q48500758 | ||
| Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). | Q48556572 | ||
| Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment | Q48625908 | ||
| Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. | Q48630979 | ||
| Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. | Q48653156 | ||
| Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study | Q48703531 | ||
| Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. | Q48784648 | ||
| Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. | Q48801542 | ||
| Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. | Q48805518 | ||
| Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study | Q48832910 | ||
| Automatic repositioning of single voxels in longitudinal 1H MRS studies | Q48856038 | ||
| Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study | Q48856161 | ||
| Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease | Q48891427 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study | Q49065999 | ||
| Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma | Q49069882 | ||
| Multicenter assessment of reliability of cranial MRI. | Q51353533 | ||
| Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. | Q51762261 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 141-157 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Dialogues in Clinical Neuroscience | Q24255736 |
| P1476 | title | Biological markers for early detection and pharmacological treatment of Alzheimer's disease | |
| P478 | volume | 11 |
| Q37820330 | APP transgenic mice: their use and limitations |
| Q33791646 | Biomarkers in Alzheimer's disease: past, present and future |
| Q33625663 | Blood-based biomarkers of microvascular pathology in Alzheimer's disease |
| Q28259585 | Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease |
| Q35997824 | Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease |
| Q34245127 | Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease. |
| Q38044199 | Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. |
| Q38080975 | Deciphering post-translational modification codes. |
| Q64092620 | Dysregulated Urinary Arginine Metabolism in Older Adults With Amnestic Mild Cognitive Impairment |
| Q92723269 | Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes |
| Q28730795 | Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset |
| Q35327219 | The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease |
| Q33624674 | Total and phosphorylated tau protein as biological markers of Alzheimer's disease |
Search more.